.png)
Highlights & Summary
Read about August 2025 digital health updates here:
Disease Management / Digital Therapeutics
Cerebral acquired Resilience Lab to expand its digital-first mental health platform with structured clinician training and integrated, outcomes-driven care. Artera received FDA De Novo authorization for its AI-based digital pathology software, the first tool approved to prognosticate outcomes in non-metastatic prostate cancer. The North Carolina State Health Plan partnered with Hello Heart to provide connected cardiovascular monitoring and digital tools to underserved communities.
Informatics / Healthcare IT Solutions
Datavant acquired Ontellus to add legal and insurance records retrieval to its data-sharing platform, expanding end-to-end real-world evidence and data linkage solutions. CHE Behavioral Health Services implemented Inbox Health’s AI billing platform to streamline patient payments, improve transparency, and reduce administrative burden. Develop Health raised $14.3M to scale its generative AI platform for automating prior authorization and medication access within EHR workflows.
Women’s Health / Femtech
Ōura launched Pregnancy Insights and Perimenopause Check-In, integrating biometric data with clinical care pathways to expand its women’s health platform. Mira released Ultra4, an at-home hormone monitor measuring four hormones with clinical-level accuracy and AI-powered insights for fertility and reproductive health. Gameto raised $44M and began Phase 3 trials of Fertilo, an iPSC-derived therapy that shortens ovarian stimulation and represents a novel approach to IVF and reproductive care.
Disease Management / Digital Therapeutics
1 | Cerebral acquires behavioral health company Resilience Lab
2 | Artera receives FDA de novo marketing authorization for ArteraAI Prostate
Informatics / Healthcare IT Solutions
1 | Datavant acquires data retrieval company Ontellus
2 | CHE Behavioral Health Services selects Inbox Health for streamlined patient billing
3 | Develop Health garners $14.3M for AI prior authorization platform
Women’s Health / Femtech
2 | Mira introduces at-home hormone monitor
News Scrape
Disease Management / Digital Therapeutics
1 | Cerebral acquires behavioral health company Resilience Lab
Cerebral has acquired Resilience Lab to expand its digital-first, integrated mental health platform with an outcomes-driven clinical training and support model. The acquisition combines Cerebral’s national reach and digital infrastructure with Resilience Lab’s methodology for developing and supervising clinicians, enabling more consistent, personalized, and coordinated care. By embedding real-time collaboration between therapists and prescribers into a single care team, Cerebral aims to address the challenges of fragmented treatment and variable outcomes in behavioral health. Resilience Lab contributes structured clinician development, burnout prevention, and measurement-informed care, ensuring treatment is guided by both evidence and data. Together, the organizations plan to scale a clinician-centered, digitally enabled model of mental healthcare designed to improve quality, reliability, and long-term outcomes nationwide.
2 | Artera receives FDA de novo marketing authorization for ArteraAI Prostate
Artera has received FDA De Novo authorization for ArteraAI Prostate, making it the first AI-powered software authorized to prognosticate outcomes for patients with non-metastatic prostate cancer. Now recognized as an FDA-regulated Software as a Medical Device (SaMD), the platform establishes a new product code category for AI-driven digital pathology risk-stratification tools. The milestone aims to address delays in prostate cancer care by delivering actionable insights earlier, helping clinicians make more confident treatment decisions.
The North Carolina State Health Plan has partnered with Hello Heart to provide preventive heart health tools to up to 55,000 eligible members in rural and underserved communities. The program, available at no cost to participants, offers a connected blood pressure monitor and app to track key health metrics such as blood pressure, cholesterol, weight, and activity. Members also receive medication adherence tools, personalized health insights, and the ability to securely share reports with providers. State Health Plan leaders emphasized the initiative’s goal of improving access to care, empowering members, and containing costs, as heart disease remains the leading cause of death in the U.S. and a growing driver of healthcare spending.
Informatics / Healthcare IT Solutions
1 | Datavant acquires data retrieval company Ontellus
Datavant, a data-sharing technology company, announced its acquisition of Ontellus, a leading records retrieval firm, to launch a new legal and insurance vertical. The move aims to streamline the secure, compliant exchange of health and billing data between providers and requesters, such as insurers and legal professionals. Ontellus brings expertise in procuring a wide range of records, including medical, employment, pharmaceutical, and claims-related data. This deal continues Datavant’s expansion strategy, following its recent acquisition of Aetion to strengthen its real-world evidence offerings and an expanded collaboration with Boehringer Ingelheim to advance RWE integration across clinical trials. Together, these steps position Datavant to deliver end-to-end solutions in data linkage, privacy, and analytics while modernizing and digitizing traditionally manual health record processes.
2 | CHE Behavioral Health Services selects Inbox Health for streamlined patient billing
CHE Behavioral Health Services has rolled out Inbox Health’s AI-enabled patient billing and communications platform across its multi-state care network, streamlining payment processes and patient support. The platform manages billing questions via live staff and AI assistants available 24/7 in 60 languages, while giving CHE real-time dashboards to monitor payments and patient feedback. Early results show strong adoption: within 60 days, 90% of payments were received in the first 15 days, 99% of patients opted for digital communications, and the company projects a 15-day decline in patient-pay DSO (Days Sales Outstanding) alongside a 75% reduction in inbound billing calls. Implementation was completed in under 40 days through integration with Qualifacts’ behavioral health EHR. For patients, the tool simplifies billing with clear statements and multiple payment options, while for CHE it reduces administrative burden, supporting the company’s broader mission of seamless health care.
3 | Develop Health raises $14.3M to automate prior authorization and medication access using GenAI
Develop Health, a San Francisco-based benefits verification and prior authorization platform, has raised $14.3M in Series A funding, bringing its total funding to $17.6M. The company offers an EHR-integrated generative AI platform that streamlines medication access by automating insurance verification and prior authorization submission. With the new capital, Develop Health plans to expand partnerships with digital health companies and beyond, deepen integrations with EHRs and PBMs, and broaden its reach into the medical benefit market. CEO Mel van Londen described the company’s vision as building “healthcare’s agentic clearinghouse,” ensuring providers have visibility into patient plans so prescriptions are both accessible and affordable. The raise comes amid broader momentum in AI-driven prior authorization.
Women’s Health / Femtech
Ōura announced two new digital health offerings focused on women’s health: a redesigned Pregnancy Insights experience and a new Perimenopause Check-In tool. The Pregnancy Insights update leverages biometric data from over 10,000 pregnancies to provide personalized tracking of physiological changes, integrated educational content, and symptom tagging, offering mothers-to-be more context and visibility into their health throughout pregnancy. Perimenopause Check-In combines validated symptom scoring with wearable data and direct access to partner clinics such as Midi Health, Evernow, Maven Clinic, and Progyny, enabling women to better track, understand, and act on their symptoms. Together, these launches expand Oura’s role beyond wearable tracking into a more comprehensive women’s health platform, integrating consumer biometrics with clinical pathways to support reproductive and midlife health.
2 | Mira introduces at-home hormone monitor
Mira announced the launch of Ultra4, an at-home hormone monitor that measures four key hormones (FSH, LH, E3G, and PdG) with lab-level accuracy using fluorescent technology. The device enables users to gain a complete picture of their hormonal health, from ovulation strength to cycle balance, and supports broader use cases beyond fertility, including perimenopause and overall reproductive health. Paired with Mira’s AI-powered app, the system offers features such as 4D Ovulation Profiling, Egg Prep Scan, Hormonal Fingerprint, Cycle Balance Analysis, and Egg Count Intelligence, providing personalized insights and tracking over time. With Ultra4, Mira is expanding its mission to make continuous hormone data more accessible and to evolve toward a comprehensive women’s health platform, with future plans for wearable, real-time hormone monitoring.
Gameto announced a $44 million Series C financing round, bringing its total funding to $127 million to advance late-stage clinical development of Fertilo, its iPSC-derived therapy for egg maturation. Fertilo is currently in a Phase 3 U.S. trial, designed as the first randomized, controlled, double-blind study of ex vivo egg maturation, and aims to shorten ovarian stimulation from two weeks of daily injections to just 2–3 days. The therapy has already been cleared in several international markets, with recorded pregnancies and live births, positioning it as a potential paradigm shift in IVF and reproductive care. Beyond Fertilo, Gameto is also developing menopause therapies through its Ameno program and leveraging an AI-powered organoid platform to accelerate women’s health drug discovery, underscoring its broader ambition to modernize reproductive and midlife care.
.png)
.png)
.png)
